{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:46:36Z","timestamp":1773078396897,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,1,14]],"date-time":"2006-01-14T00:00:00Z","timestamp":1137196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1007\/s00277-005-0054-4","type":"journal-article","created":{"date-parts":[[2006,1,13]],"date-time":"2006-01-13T10:11:08Z","timestamp":1137147068000},"page":"263-267","source":"Crossref","is-referenced-by-count":36,"title":["Plasma cell leukemia: a rare condition"],"prefix":"10.1007","volume":"85","author":[{"given":"V\u00edctor Hugo","family":"Jim\u00e9nez-Zepeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia Jeanet","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,1,14]]},"reference":[{"issue":"3","key":"54_CR1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11864-001-0034-4","volume":"2","author":"SR Hayman","year":"2001","unstructured":"Hayman SR, Fonseca R (2001) Plasma cell leukemia. Curr Treat Options Oncol 2(3):205\u2013216","journal-title":"Curr Treat Options Oncol"},{"key":"54_CR2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/jcp.42.6.567","volume":"42","author":"JM Bennet","year":"1989","unstructured":"Bennet JM, Catowsky D, Daniel M-T, Flandrin G et al (1989) Proposals for the classification of chronic (mature) B and T cell lymphoid leukemias. J Clin Pathol 42:567","journal-title":"J Clin Pathol"},{"key":"54_CR3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.133.5.813","volume":"133","author":"RA Kyle","year":"1974","unstructured":"Kyle RA, Maldonado JE, Bayrd ED (1974) Plasma cell leukemia. Report on 17 cases. Arch Intern Med 133:813","journal-title":"Arch Intern Med"},{"key":"54_CR4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/0002-9343(87)90942-9","volume":"83","author":"P Noel","year":"1987","unstructured":"Noel P, Kyle RA (1987) Plasma cell leukemia: an evaluation of response to therapy. Am J Med 83:1062","journal-title":"Am J Med"},{"key":"54_CR5","volume-title":"Blood cells: a practical guide","author":"BJ Baim","year":"1995","unstructured":"Baim BJ (1995) Blood cells: a practical guide. Blackwell Science, Oxford, UK"},{"issue":"4","key":"54_CR6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.thj.6200375","volume":"5","author":"S Wohrer","year":"2004","unstructured":"Wohrer S, Ackermann J, Baldia C et al (2004) Effective treatment of primary plasma cell leukaemia with thalidomide and dexamethasone\u2014a case report. Hematol J 5(4):361\u2013363","journal-title":"Hematol J"},{"key":"54_CR7","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb05114.x","volume":"88","author":"MA Dimopoulos","year":"1994","unstructured":"Dimopoulos MA, Palumbo A, Delasalle KB et al (1994) Primary plasma cell leukemia. Br J Haematol 88:754","journal-title":"Br J Haematol"},{"issue":"1","key":"54_CR8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","volume":"3","author":"Garcia Sanz","year":"1999","unstructured":"Garcia Sanz, Orfao M, Tabernero J et al (1999) Primary plasma cell leukemia: immunophenotypic, DNA ploidy and cytogenetic characteristics. Blood 3(1):1032\u20131037","journal-title":"Blood"},{"key":"54_CR9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-2002-33857","volume":"23","author":"U Jehn","year":"2002","unstructured":"Jehn U (2002) Diagnostik und therapie der plasmazell-leukamie. Tumordiagn Ther 23:135\u2013136","journal-title":"Tumordiagn Ther"},{"key":"54_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/10428199609067575","volume":"21","author":"M Taniwaki","year":"1996","unstructured":"Taniwaki M, Nishida K, Ueda et al (1996) Non random chromosomal rearrangements and their implications in clinical features and outcome in multiple myeloma and plasma cell leukaemia. Leuk Lymphoma 21:25\u201330","journal-title":"Leuk Lymphoma"},{"key":"54_CR11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0889-8588(05)70125-8","volume":"13","author":"J Blade","year":"1999","unstructured":"Blade J, Kyle RA (1999) Nonsecretory myeloma, immunoglobulin D myeloma and plasma cell leukaemia. Hematol Oncol Clin North Am 13:1229\u20131279","journal-title":"Hematol Oncol Clin North Am"},{"key":"54_CR12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1600-0609.1995.tb00695.x","volume":"54","author":"M Bjorkholm","year":"1995","unstructured":"Bjorkholm M, Osby E (1995) Fludarabine and plasma cell leukemia. Eur J Haematol 54:334\u2013335","journal-title":"Eur J Haematol"},{"key":"54_CR13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.1991.tb07975.x","volume":"77","author":"JF Miguel San","year":"1991","unstructured":"San Miguel JF, Garc\u00eda-Sanz R, Gonz\u00e1lez M et al (1991) Immunophenotype heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Br J Haematol 77:185","journal-title":"Br J Haematol"},{"key":"54_CR14","first-page":"2173","volume":"3","author":"M Urashima","year":"1997","unstructured":"Urashima M, Teoh G, Ogata A et al (1997) Characterization of p16 (INK4A) expression in multiple myeloma and plasma cell leukaemia. Clin Cancer Res 3:2173\u20132179","journal-title":"Clin Cancer Res"},{"key":"54_CR15","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/sj.leu.2401211","volume":"12","author":"C Pellat-Deceunynck","year":"1998","unstructured":"Pellat-Deceunynck C, Barille S, Jego G et al (1998) The absence of CD56 on malignant plasma cells is a hallmark of plasma cell leukaemia and of a special subset of multiple myeloma. Leukemia 12:1977\u20131982","journal-title":"Leukemia"},{"key":"54_CR16","first-page":"161","volume":"149","author":"MD Tabernero","year":"1996","unstructured":"Tabernero MD, San Miguel JF, Garc\u00eda-Sanz R et al (1996) Incidence of chromosome numerical changes in multiple myeloma. A FISH analysis using 15 chromosome specific probes. Am J Pathol 149:161","journal-title":"Am J Pathol"},{"issue":"1","key":"54_CR17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-4608(03)00233-4","volume":"148","author":"E Lloveras","year":"2004","unstructured":"Lloveras E (2004) Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukaemia. Cancer Genet Cytogenet 148(1):71\u201376","journal-title":"Cancer Genet Cytogenet"},{"issue":"4","key":"54_CR18","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1046\/j.1365-2141.2002.03537_4.x","volume":"117","author":"F Bauduer","year":"2002","unstructured":"Bauduer F (2002) Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia after autologous stem cell transplantation for multiple myeloma. Br J Haematol 117(4):996","journal-title":"Br J Haematol"},{"issue":"7","key":"54_CR19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00277-002-0480-5","volume":"81","author":"J Vela-Ojeda","year":"2002","unstructured":"Vela-Ojeda J, Garcia Ru\u00edz EMA, Rosas-Cabral A et al (2002) Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin and dexamethasone and polychemotherapy for the treatment of primary plasma cells leukaemia. Ann Hematol 81(7):362\u2013367","journal-title":"Ann Hematol"},{"key":"54_CR20","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","volume":"109","author":"T Hideshima","year":"2000","unstructured":"Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human myeloma cells to conventional therapy. Blood 109:2943\u20132950","journal-title":"Blood"},{"issue":"2","key":"54_CR21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/10428190290006143","volume":"43","author":"RE Johnston","year":"2002","unstructured":"Johnston RE, Abdalla SH (2002) Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma 43(2):351\u2013354","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"54_CR22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ijc.20793","volume":"114","author":"A Esparis-Ogando","year":"2005","unstructured":"Esparis-Ogando A, Alegre A, Aguado B et al (2005) Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 114(4):665\u2013667","journal-title":"Int J Cancer"},{"issue":"1","key":"54_CR23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1034\/j.1600-0609.2001.067001051.x","volume":"67","author":"L Christou","year":"2001","unstructured":"Christou L, Hatzimichael E, Chaidos A et al (2001) Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone. Eur J Haematol 67(1):51\u201353","journal-title":"Eur J Haematol"},{"issue":"1","key":"54_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2257.2003.00485.x","volume":"25","author":"YK Mak","year":"2003","unstructured":"Mak YK, Chan CH, Chen YT et al (2003) Consolidation therapy with autologous blood stem cell transplantation in a patient with primary plasma cell leukaemia. Clin Lab Haematol 25(1):55\u201358","journal-title":"Clin Lab Haematol"},{"issue":"2","key":"54_CR25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00277-001-0397-4","volume":"81","author":"C Gemmel","year":"2002","unstructured":"Gemmel C, Cremer FW, Weis M et al (2002) Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukaemia after high dose therapy and autologous stem cell transplantation. Ann Hematol 81(2):119\u2013123","journal-title":"Ann Hematol"},{"key":"54_CR26","first-page":"1","volume-title":"Concise review of the disease and treatment options. Multiple myeloma","author":"BGM Durie","year":"2005","unstructured":"Durie BGM (2005) Concise review of the disease and treatment options. Multiple myeloma. International Myeloma Foundation, California, pp 1\u201339"},{"issue":"15","key":"54_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie GM et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):1\u201320","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"54_CR28","first-page":"0838","volume":"1","author":"N Goldenberg","year":"2003","unstructured":"Goldenberg N, Kahn SR, Solymoss S (2003) Activated protein C resistance in cancer-associated venous thromboembolism. J Thromb Haemost 1(Suppl 1):p0838 (abstract)","journal-title":"J Thromb Haemost"},{"key":"54_CR29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","volume":"13","author":"M Zangari","year":"2002","unstructured":"Zangari M, Saghafifar F, Anaissie E et al (2002) Acquired activated protein C resistance in the absence of Factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13:187\u2013192","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"54_CR30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1046\/j.1365-2141.2003.04720.x","volume":"123","author":"SR Deitcher","year":"2003","unstructured":"Deitcher SR, Choueiri T, Srkalovic G et al (2003) Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. Br J Haematol 123(5):959\u2013960","journal-title":"Br J Haematol"},{"issue":"3","key":"54_CR31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/0019-509X.13059","volume":"40","author":"RS Raj","year":"2003","unstructured":"Raj RS, Najeeb S, Aruna R et al (2003) Primary plasma cell leukaemia occurring in the young. Indian J Cancer 40(3):116\u2013117","journal-title":"Indian J Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-005-0054-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-005-0054-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-005-0054-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T05:19:01Z","timestamp":1683350341000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-005-0054-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,14]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["54"],"URL":"https:\/\/doi.org\/10.1007\/s00277-005-0054-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,14]]}}}